Cassava Sciences, Inc. (SAVA)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 26.34 |
| Open | 26.28 |
| Bid | 26.00 x 1400 |
| Ask | 26.30 x 3100 |
| Day's Range | 25.80 - 26.56 |
| 52 Week Range | 13.84 - 51.59 |
| Volume | |
| Avg. Volume | 1,364,403 |
| Market Cap | 1.091B |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 13, 2012 |
| 1y Target Est | 84.00 |
- Simply Wall St.
The three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasing
While Cassava Sciences, Inc. (NASDAQ:SAVA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 22%...
- Thomson Reuters StreetEvents
Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call
Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call
- GlobeNewswire
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease.In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study.In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease.Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside of Neurodegeneration.Cash And Cash Equivalents Were $201 Million at Decemb
© 2023 Yahoo. All rights reserved.
